Reported Earnings • Aug 10
First quarter 2027 earnings released: EPS: ₹3.31 (vs ₹3.57 in 1Q 2026) First quarter 2027 results: EPS: ₹3.31 (down from ₹3.57 in 1Q 2026). Revenue: ₹2.03b (up 9.1% from 1Q 2026). Net income: ₹370.9m (down 7.1% from 1Q 2026). Profit margin: 18% (down from 22% in 1Q 2026). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Board Change • Aug 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. Additional Independent Director Pradip Shah was the last director to join the board, commencing their role in 2026. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Jul 20
Upcoming dividend of ₹1.35 per share Eligible shareholders must have bought the stock before 24 July 2026. Payment date: 30 August 2026. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 1.7%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.8%). Reported Earnings • Jul 10
Full year 2026 earnings: EPS and revenues exceed analyst expectations Full year 2026 results: EPS: ₹15.08 (up from ₹11.72 in FY 2025). Revenue: ₹7.46b (up 17% from FY 2025). Net income: ₹1.69b (up 29% from FY 2025). Profit margin: 23% (up from 21% in FY 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 5% per year. Ankündigung • Jul 06
Advanced Enzyme Technologies Limited, Annual General Meeting, Jul 31, 2026 Advanced Enzyme Technologies Limited, Annual General Meeting, Jul 31, 2026, at 10:00 Indian Standard Time. Declared Dividend • Jul 06
Dividend of ₹1.35 announced Shareholders will receive a dividend of ₹1.35. Ex-date: 24th July 2026 Payment date: 30th August 2026 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (35% earnings payout ratio) and cash flows (57% cash payout ratio). The dividend has increased by an average of 33% per year over the past 9 years and payments have been stable during that time. EPS is expected to grow by 21% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Ankündigung • Jul 05
Advanced Enzyme Technologies Limited announces Annual dividend, payable on August 30, 2026 Advanced Enzyme Technologies Limited announced Annual dividend of INR 1.3500 per share payable on August 30, 2026, ex-date on July 24, 2026 and record date on July 24, 2026. Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹308, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 13% over the past three years. Ankündigung • Jun 12
Advanced Enzyme Technologies Limited Announces Cessation of Rajshree Patel as Independent Director, Effective June 11, 2026 Advanced Enzyme Technologies Limited announced that Ms. Rajshree Patel (DIN – 08761022) ceased to be the Director of the Company with effect from end of business hours on June 11, 2026, due to completion of her second term as an Independent Director of the Company. Reported Earnings • May 11
Full year 2026 earnings: EPS and revenues exceed analyst expectations Full year 2026 results: EPS: ₹15.08 (up from ₹11.72 in FY 2025). Revenue: ₹7.81b (up 23% from FY 2025). Net income: ₹1.69b (up 29% from FY 2025). Profit margin: 22% (up from 21% in FY 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 11% per year. Ankündigung • May 02
Advanced Enzyme Technologies Limited to Report Q4, 2026 Results on May 09, 2026 Advanced Enzyme Technologies Limited announced that they will report Q4, 2026 results at 9:08 AM, Indian Standard Time on May 09, 2026 Valuation Update With 7 Day Price Move • Apr 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹348, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 32% over the past three years. Reported Earnings • Feb 01
Third quarter 2026 earnings released: EPS: ₹3.80 (vs ₹3.36 in 3Q 2025) Third quarter 2026 results: EPS: ₹3.80 (up from ₹3.36 in 3Q 2025). Revenue: ₹1.72b (up 1.7% from 3Q 2025). Net income: ₹425.0m (up 13% from 3Q 2025). Profit margin: 25% (up from 22% in 3Q 2025). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Ankündigung • Jan 23
Advanced Enzyme Technologies Limited to Report Q3, 2026 Results on Jan 31, 2026 Advanced Enzyme Technologies Limited announced that they will report Q3, 2026 results on Jan 31, 2026 Ankündigung • Nov 04
Advanced Enzyme Technologies Limited to Report Q2, 2026 Results on Nov 12, 2025 Advanced Enzyme Technologies Limited announced that they will report Q2, 2026 results on Nov 12, 2025 Valuation Update With 7 Day Price Move • Aug 09
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹305, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 21% over the past three years. Board Change • Aug 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. Independent Director Vandana Tilak was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Jul 25
Advanced Enzyme Technologies Limited to Report Q1, 2026 Results on Aug 02, 2025 Advanced Enzyme Technologies Limited announced that they will report Q1, 2026 results on Aug 02, 2025 Upcoming Dividend • Jul 16
Upcoming dividend of ₹1.20 per share Eligible shareholders must have bought the stock before 23 July 2025. Payment date: 29 August 2025. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 1.6%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%). Reported Earnings • Jul 08
Full year 2025 earnings released: EPS: ₹11.72 (vs ₹11.92 in FY 2024) Full year 2025 results: EPS: ₹11.72 (down from ₹11.92 in FY 2024). Revenue: ₹6.37b (up 2.1% from FY 2024). Net income: ₹1.31b (down 1.6% from FY 2024). Profit margin: 21% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 6% per year. Declared Dividend • Jun 11
Dividend of ₹1.20 announced Shareholders will receive a dividend of ₹1.20. Ex-date: 23rd July 2025 Payment date: 29th August 2025 Dividend yield will be 1.6%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (43% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 38% per year over the past 8 years and payments have been stable during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend. Declared Dividend • May 15
Dividend of ₹4.00 announced Shareholders will receive a dividend of ₹4.00. Ex-date: 16th May 2025 Payment date: 12th June 2025 Dividend yield will be 1.8%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (43% earnings payout ratio) and cash flows (63% cash payout ratio). The dividend has increased by an average of 37% per year over the past 8 years and payments have been stable during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend. New Risk • Feb 13
New major risk - Revenue and earnings growth Earnings have declined by 1.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 09
Third quarter 2025 earnings released: EPS: ₹3.36 (vs ₹3.74 in 3Q 2024) Third quarter 2025 results: EPS: ₹3.36 (down from ₹3.74 in 3Q 2024). Revenue: ₹1.69b (up 5.1% from 3Q 2024). Net income: ₹376.5m (down 9.9% from 3Q 2024). Profit margin: 22% (down from 26% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Ankündigung • Feb 01
Advanced Enzyme Technologies Limited to Report Q3, 2025 Results on Feb 08, 2025 Advanced Enzyme Technologies Limited announced that they will report Q3, 2025 results on Feb 08, 2025 Valuation Update With 7 Day Price Move • Nov 16
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to ₹380, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 17% over the past three years. Reported Earnings • Nov 12
Second quarter 2025 earnings released: EPS: ₹2.94 (vs ₹3.08 in 2Q 2024) Second quarter 2025 results: EPS: ₹2.94 (down from ₹3.08 in 2Q 2024). Revenue: ₹1.46b (down 7.4% from 2Q 2024). Net income: ₹328.3m (down 4.6% from 2Q 2024). Profit margin: 23% (in line with 2Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year. New Risk • Nov 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Significant insider selling over the past 3 months (₹52m sold). Ankündigung • Oct 31
Advanced Enzyme Technologies Limited to Report Q2, 2025 Results on Nov 09, 2024 Advanced Enzyme Technologies Limited announced that they will report Q2, 2025 results on Nov 09, 2024 Recent Insider Transactions • Sep 16
Insider recently sold ₹51m worth of stock On the 11th of September, Mangala Kabra sold around 100k shares on-market at roughly ₹509 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹68m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Sep 13
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹534, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 33x in the Chemicals industry in India. Total returns to shareholders of 38% over the past three years. Valuation Update With 7 Day Price Move • Aug 19
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹468, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 32% over the past three years. Reported Earnings • Aug 11
First quarter 2025 earnings released: EPS: ₹3.05 (vs ₹2.58 in 1Q 2024) First quarter 2025 results: EPS: ₹3.05 (up from ₹2.58 in 1Q 2024). Revenue: ₹1.62b (up 9.7% from 1Q 2024). Net income: ₹341.5m (up 19% from 1Q 2024). Profit margin: 21% (up from 20% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 2% per year. Ankündigung • Aug 02
Advanced Enzyme Technologies Limited to Report Q1, 2025 Results on Aug 10, 2024 Advanced Enzyme Technologies Limited announced that they will report Q1, 2025 results on Aug 10, 2024 Ankündigung • Jul 27
Advanced Enzyme Technologies Approves Final Dividend for the Financial Year Ended March 31, 2024 Advanced Enzyme Technologies Limited at its 35th AGM held on July 25, 2024 approved final Dividend (INR 1.10 per Equity Share) on the Equity Shares of 2 each, for the financial year ended March 31, 2024. Upcoming Dividend • Jul 11
Upcoming dividend of ₹1.10 per share Eligible shareholders must have bought the stock before 18 July 2024. Payment date: 24 August 2024. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 1.3%. Within top quartile of Indian dividend payers (1.1%). Higher than average of industry peers (0.7%). Reported Earnings • Jul 05
Full year 2024 earnings released: EPS: ₹11.92 (vs ₹9.45 in FY 2023) Full year 2024 results: EPS: ₹11.92 (up from ₹9.45 in FY 2023). Revenue: ₹6.24b (up 15% from FY 2023). Net income: ₹1.33b (up 26% from FY 2023). Profit margin: 21% (up from 20% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has remained flat. Ankündigung • Jun 28
Advanced Enzyme Technologies Limited, Annual General Meeting, Jul 25, 2024 Advanced Enzyme Technologies Limited, Annual General Meeting, Jul 25, 2024, at 10:00 Indian Standard Time. Recent Insider Transactions • Jun 26
Insider recently sold ₹11m worth of stock On the 20th of June, Chandrakanth Kumar Rathi sold around 29k shares on-market at roughly ₹392 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹24m more than they bought in the last 12 months. Recent Insider Transactions • Jun 22
Insider recently sold ₹6.9m worth of stock On the 14th of June, Chandrakanth Kumar Rathi sold around 18k shares on-market at roughly ₹396 per share. This transaction amounted to 38% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹13m more than they bought in the last 12 months. Recent Insider Transactions • Jun 20
Insider recently sold ₹6.9m worth of stock On the 14th of June, Chandrakanth Kumar Rathi sold around 18k shares on-market at roughly ₹396 per share. This transaction amounted to 38% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹4.9m more than they bought in the last 12 months. Declared Dividend • May 15
Final dividend of ₹4.00 announced Shareholders will receive a dividend of ₹4.00. Ex-date: 17th May 2024 Payment date: 5th June 2024 Dividend yield will be 1.3%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (11% earnings payout ratio) and cash flows (48% cash payout ratio). The dividend has increased by an average of 39% per year over the past 7 years and payments have been stable during that time. Earnings per share has grown by 3.7% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • May 13
Full year 2024 earnings released: EPS: ₹11.92 (vs ₹9.45 in FY 2023) Full year 2024 results: EPS: ₹11.92 (up from ₹9.45 in FY 2023). Revenue: ₹6.61b (up 22% from FY 2023). Net income: ₹1.33b (up 26% from FY 2023). Profit margin: 20% (in line with FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 6% per year. Ankündigung • May 06
Advanced Enzyme Technologies Limited to Report Q4, 2024 Results on May 11, 2024 Advanced Enzyme Technologies Limited announced that they will report Q4, 2024 results on May 11, 2024 Ankündigung • Mar 07
Advanced Enzyme Technologies Limited (NSEI:ADVENZYMES) acquired additional 5.89% stake in Jc Biotech Private Limited for INR 56.1 million Advanced Enzyme Technologies Limited (NSEI:ADVENZYMES) agreed to acquire additional 5.89% stake in Jc Biotech Private Limited for INR 56.1 million on February 10, 2024. Advanced Enzyme currently holds 89.83% stake in Jc Biotech and post completion of the transaction Advanced Enzyme will hold 95.72% stake in Jc Biotech. Jc Biotech reported turnover of INR 502 million and loss after tax of INR 18.42 million for FY2022-23. Board of Advanced Enzyme approved the transaction. The transaction is expected to close on March 31, 2024.
Advanced Enzyme Technologies Limited (NSEI:ADVENZYMES) completed the acquisition of additional 5.89% stake in Jc Biotech Private Limited on March 5, 2024. Reported Earnings • Feb 11
Third quarter 2024 earnings released: EPS: ₹3.74 (vs ₹2.63 in 3Q 2023) Third quarter 2024 results: EPS: ₹3.74 (up from ₹2.63 in 3Q 2023). Revenue: ₹1.75b (up 23% from 3Q 2023). Net income: ₹417.7m (up 42% from 3Q 2023). Profit margin: 24% (up from 21% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Ankündigung • Feb 05
Advanced Enzyme Technologies Limited to Report Q3, 2024 Results on Feb 10, 2024 Advanced Enzyme Technologies Limited announced that they will report Q3, 2024 results on Feb 10, 2024 New Risk • Dec 28
New major risk - Revenue and earnings growth Earnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. New Risk • Nov 08
New major risk - Revenue and earnings growth Earnings have declined by 0.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.4% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Ankündigung • Nov 01
Advanced Enzyme Technologies Limited to Report Q2, 2024 Results on Nov 07, 2023 Advanced Enzyme Technologies Limited announced that they will report Q2, 2024 results on Nov 07, 2023 Reported Earnings • Aug 13
First quarter 2024 earnings released: EPS: ₹2.58 (vs ₹1.60 in 1Q 2023) First quarter 2024 results: EPS: ₹2.58 (up from ₹1.60 in 1Q 2023). Revenue: ₹1.47b (up 22% from 1Q 2023). Net income: ₹288.1m (up 61% from 1Q 2023). Profit margin: 20% (up from 15% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Ankündigung • Aug 13
Advanced Enzyme Technologies Declares Final Dividend for the Financial Year Ended March 31, 2023 Advanced Enzyme Technologies Limited at the AGM held on August 12, 2023 declared final Dividend (INR 1 per Equity Share) on the Equity Shares of 2each, for the financial year ended March 31, 2023. Ankündigung • Aug 05
Advanced Enzyme Technologies Limited to Report Q1, 2024 Results on Aug 12, 2023 Advanced Enzyme Technologies Limited announced that they will report Q1, 2024 results on Aug 12, 2023 Upcoming Dividend • Jul 28
Upcoming dividend of ₹1.00 per share at 1.2% yield Eligible shareholders must have bought the stock before 04 August 2023. Payment date: 11 September 2023. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.9%). Reported Earnings • Jul 15
Full year 2023 earnings: Revenues and EPS in line with analyst expectations Full year 2023 results: EPS: ₹9.45 (down from ₹10.70 in FY 2022). Revenue: ₹5.41b (up 2.1% from FY 2022). Net income: ₹1.06b (down 12% from FY 2022). Profit margin: 20% (down from 23% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Ankündigung • Jul 09
Advanced Enzyme Technologies Limited Proposes Dividend Payable on or After August 16, 2023 The 34th Annual General Meeting ("AGM") of the Advanced Enzyme Technologies Limited will be held on August 12, 2023. Pursuant to Regulation 42 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to letter dated May 13,2023 intimating that Dividend of INR 1 per Equity Share of INR 2 each for the financial year 2022-23 (FY23) recommended by the Board of Directors of the Company, it is hereby informed that Record Date has been fixed as August 05, 2023, for the purpose of ascertaining the entitlement of the Members to the said final dividend for Fiscal 2023, if approved (declared) at the 34th AGM. If the Dividend is approved by the Members as mentioned above: the said Dividend shall be paid on or after August 16, 2023 to the Members whose names appear in the Register of Members or as beneficial owners as on August 05, 2023; and in the cases where the ECS mandates of the Members are not available to enable the payment of Dividend electronically, the Dividend warrant/drafts/cheques shall be sent in due course. Board Change • Jul 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Independent Director Nitin Deshmukh was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Jun 18
Chairman recently bought ₹142m worth of stock On the 15th of June, Vasant Rathi bought around 515k shares on-market at roughly ₹275 per share. This transaction amounted to 1.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Vasant's only on-market trade for the last 12 months. Recent Insider Transactions • Jun 05
Chairman recently bought ₹2.7m worth of stock On the 31st of May, Vasant Rathi bought around 10k shares on-market at roughly ₹275 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Vasant's only on-market trade for the last 12 months. Reported Earnings • May 14
Full year 2023 earnings: Revenues and EPS in line with analyst expectations Full year 2023 results: EPS: ₹9.45 (down from ₹10.70 in FY 2022). Revenue: ₹5.66b (up 6.9% from FY 2022). Net income: ₹1.06b (down 12% from FY 2022). Profit margin: 19% (down from 23% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Ankündigung • May 07
Advanced Enzyme Technologies Limited to Report Q4, 2023 Results on May 13, 2023 Advanced Enzyme Technologies Limited announced that they will report Q4, 2023 results on May 13, 2023 Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: ₹2.63 (vs ₹2.46 in 3Q 2022) Third quarter 2023 results: EPS: ₹2.63 (up from ₹2.46 in 3Q 2022). Revenue: ₹1.51b (up 13% from 3Q 2022). Net income: ₹294.4m (up 7.1% from 3Q 2022). Profit margin: 20% (down from 21% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Ankündigung • Feb 05
Advanced Enzyme Technologies Limited to Report Q3, 2023 Results on Feb 11, 2023 Advanced Enzyme Technologies Limited announced that they will report Q3, 2023 results on Feb 11, 2023 Ankündigung • Jan 04
Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 4.83% stake in JC Biotech Private Limited. Advanced Enzyme Technologies Limited (BSE:540025) agreed to acquire additional 4.83% stake in JC Biotech Private Limited for INR 68 million on November 11, 2022. Advanced Enzyme Technologies Limited will acquire 1 million shares of JC Biotech Private Limited. JC Biotech Private Limited reported Turnover of INR 504 million and Net income of INR 73 million in year ending March 31, 2022. The transaction was approved by Advanced Enzyme Technologies Limited Board of directors. The transaction was expected to complete on January 31, 2023.
Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 4.83% stake in JC Biotech Private Limited on January 3, 2022. Price Target Changed • Nov 16
Price target decreased to ₹265 Down from ₹333, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of ₹274. Stock is down 20% over the past year. The company is forecast to post earnings per share of ₹8.50 for next year compared to ₹10.70 last year. Ankündigung • Nov 05
Advanced Enzyme Technologies Limited to Report Q2, 2023 Results on Nov 11, 2022 Advanced Enzyme Technologies Limited announced that they will report Q2, 2023 results at 12:15 PM, Indian Standard Time on Nov 11, 2022 Recent Insider Transactions • Sep 23
Insider recently sold ₹100m worth of stock On the 19th of September, Savita Rathi sold around 372k shares on-market at roughly ₹270 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹101m more than they bought in the last 12 months. Upcoming Dividend • Aug 04
Upcoming dividend of ₹1.00 per share Eligible shareholders must have bought the stock before 11 August 2022. Payment date: 18 September 2022. Payout ratio is a comfortable 9.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.7%). Lower than average of industry peers (0.7%). Reported Earnings • Jul 29
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: ₹10.70 (down from ₹13.07 in FY 2021). Revenue: ₹5.29b (up 5.5% from FY 2021). Net income: ₹1.20b (down 18% from FY 2021). Profit margin: 23% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 7.3%, compared to a 15% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Jul 22
Advanced Enzyme Technologies Limited, Annual General Meeting, Aug 19, 2022 Advanced Enzyme Technologies Limited, Annual General Meeting, Aug 19, 2022, at 10:00 Indian Standard Time. Reported Earnings • May 22
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: ₹10.70 (down from ₹13.09 in FY 2021). Revenue: ₹5.29b (up 5.5% from FY 2021). Net income: ₹1.20b (down 18% from FY 2021). Profit margin: 23% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 14%, compared to a 21% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • May 21
Advanced Enzyme Technologies Limited Recommends Dividend for the Financial Year Ended March 31, 2022 The Board of Directors of Advanced Enzyme Technologies Limited at its Meeting held on May 20, 2022, Recommended a Dividend at the rate of 50% that is INR 1 per Equity Share on the face value of INR 2 each for the financial year ended March 31, 2022, subject to the approval of the Shareholders at the upcoming 33rd Annual General Meeting of the Company ("AGM"). The Dividend, if approved /declared by the Shareholders at 33rd AGM, will be paid on and from the second day from the date of AGM. Record date for the entitlement of Dividend, and date & timings for upcoming Annual General Meeting of the Company shall be intimated in due course of time. Ankündigung • May 13
Advanced Enzyme Technologies Limited to Report Q4, 2022 Results on May 20, 2022 Advanced Enzyme Technologies Limited announced that they will report Q4, 2022 results on May 20, 2022 Price Target Changed • Apr 27
Price target increased to ₹380 Up from ₹333, the current price target is provided by 1 analyst. New target price is 25% above last closing price of ₹305. Stock is down 25% over the past year. The company is forecast to post earnings per share of ₹11.30 for next year compared to ₹13.09 last year. Valuation Update With 7 Day Price Move • Mar 01
Investor sentiment improved over the past week After last week's 16% share price gain to ₹319, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 112% over the past three years. Reported Earnings • Feb 08
Third quarter 2022 earnings: EPS misses analyst expectations Third quarter 2022 results: EPS: ₹2.46 (down from ₹3.86 in 3Q 2021). Revenue: ₹1.35b (down 2.6% from 3Q 2021). Net income: ₹274.8m (down 36% from 3Q 2021). Profit margin: 20% (down from 31% in 3Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.3%. Over the next year, revenue is forecast to grow 22%, compared to a 20% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Jan 28
Advanced Enzyme Technologies Limited Announces Demise of Vilas Aurangabadkar, Independent Director Advanced Enzyme Technologies Limited announces demise of Vilas Aurangabadkar, Independent Director of the Company on January 27, 2022. Recent Insider Transactions • Jan 08
Insider recently sold ₹611k worth of stock On the 31st of December, Santosh Ingale sold around 2k shares on-market at roughly ₹326 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹6.3m more than they bought in the last 12 months. Reported Earnings • Nov 03
Second quarter 2022 earnings released: EPS ₹2.66 (vs ₹3.33 in 2Q 2021) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹1.28b (up 5.8% from 2Q 2021). Net income: ₹297.0m (down 20% from 2Q 2021). Profit margin: 23% (down from 31% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Sep 15
Advanced Enzymes Announces Positive Clinical Breakthrough in the Randomized Controlled Trials of Systemic Enzymes and Probiotics to Resolve Long Covid' Fatigue Symptoms Advanced Enzyme Technologies Limited announced that its systemic enzyme and probiotic supplements--ImmunoSEB and ProbioSEB CSC3 have passed the promising stages of randomized controlled clinical trials in terms of efficacy to resolve postCOVID fatigue symptoms. It's a fact that muscle fatigue and cognitive disturbances persist in patients after recovery from acute COVID19 disease. However, there are no specific treatments available globally to treat postCOVID fatigue complications. With an aim to evaluate the efficacy and safety of the health supplements ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex) in patients suffering from COVID19 induced fatigue, a randomized, multicentric, double blind and placebocontrolled trial was conducted in 200 patients suffering from postCOVID fatigue symptoms. The test arm (100 patients) received the oral supplements for 14days and the control arm (100 patients) received placebo, informed Dr. Abhijit K. Rathi, Principal Scientist, AETL. The randomized clinical trial was conducted on 200 patients that did not have an active SARSCoV2 infection, as determined by a negative COVID19 test, with a complaint of postCOVID fatigue. Patients were required to have a positive COVID19 test at any time in the past. The trial was conducted across three centres in India--Swasthya Hospital, Bhopal; Samvedna Hospital, Varanasi; and Chirayu Medical College & Hospital, Bhopal by Investigators for 14days, informed Dr. Rathi. According to the clinical research paper published by the Switzerlandbased "Medicines" Journal on August 30, 2021, the treatment efficacy was compared using the Chalder Fatigue Scale (CFQ11) for 14days. Interestingly, the supplemental treatment resulted in resolution of fatigue in a greater percentage in patients during the test as against the control arm (91% vs. 15%) during the 14day trial. Patients in the test arm category showed a significantly greater reduction the overall physical and mental fatigue scores as against patients in the control arm segment. The supplements were well tolerated with no adverse events reported. This clinical study demonstrated that the 14day supplementation of ImmunoSEB and ProbioSEB CSC3 resolved postCOVID19 fatigue symptoms and improved patients' functional status and quality of life, informed Dr. Rathi. The Coronavirus disease19 (COVID19) caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV2), is a worldwide pandemic afflicting a large population across the globe. Most infected people develop acute symptoms that last for 7-10 days. However, one or more symptoms (physical, cognitive and/or psychological) persist for weeks or even months in a substantial percentage of people. Fatigue is the most persistent and debilitating symptom of long COVID. Studies revealed that about 52% of patients among the studied population showed fatigue/myalgia postCOVID19. A survey done by the Office for National Statistics (ONS), United Kingdom suggests that about one in five people have symptoms of long COVID five weeks after an initial infection and one in ten after twelve weeks. The chronic phase of COVID19 is conjectured to be perpetual, with impaired functional status and quality of life. Though the data on COVID fatigue is still emerging, viral infections are known to trigger chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME) in patients. There are no specific biomarkers, and diagnosis is typically based on symptoms. Upcoming Dividend • Aug 24
Upcoming dividend of ₹0.90 per share Eligible shareholders must have bought the stock before 31 August 2021. Payment date: 08 October 2021. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.7%). Ankündigung • Aug 19
Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 15% minority stake in JC Biotech Private Limited. Advanced Enzyme Technologies Limited (BSE:540025) agreed to acquire additional 15% minority stake in JC Biotech Private Limited for approximately INR 210 million on May 29, 2021. Advanced Enzyme Technologies Limited will acquire 31.1 million equity shares of JC Biotech Private Limited at a price of INR 68 per share. Post completion of the transaction, Advanced Enzyme Technologies Limited's stake in JC Biotech Private Limited will increase from 70% to 85%. For the year 2020 to 2021, JC Biotech Private Limited reported Turnover of approximately INR 500 million and Profit After Tax of INR 78 million. On May 29, 2021, Board of Directors of Advanced Enzyme Technologies Limited approved the transaction. As of May 29, 2021, Advanced Enzyme Technologies Limited has also obtained approval of the Audit Committee as well. The transaction is expected to close by September 30, 2021.
Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 15% minority stake in JC Biotech Private Limited on August 18, 2021. Reported Earnings • Aug 09
First quarter 2022 earnings released: EPS ₹3.40 (vs ₹3.07 in 1Q 2021) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹1.38b (up 24% from 1Q 2021). Net income: ₹380.4m (up 11% from 1Q 2021). Profit margin: 28% (down from 31% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 30
Full year 2021 earnings released: EPS ₹13.09 (vs ₹11.58 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2021 results: Revenue: ₹5.11b (up 14% from FY 2020). Net income: ₹1.46b (up 13% from FY 2020). Profit margin: 29% (in line with FY 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • May 30
Advanced Enzyme Technologies Limited Recommends Dividend for the Financial Year Ended March 31, 2021 Advanced Enzyme Technologies Limited announced at the board meeting held on May 29, 2021, recommended a dividend @45%, that is INR 0.90 per equity share on the face value of INR 2 each for the financial year ended March 31, 2021, subject to the approval of the shareholders at the upcoming 32nd AGM of the company. The Dividend, if approved /declared by the Shareholders at 32nd AGM, will be paid on and from the second (2nd) day from the date of AGM. 
